IntelliPharmaCeutics International (IPCIF)
OTHER OTC:IPCIF
IPCIF
IntelliPharmaCeutics International
RESEARCH TOOLSreports
Holding IPCIF?
Track your performance easily

IntelliPharmaCeutics International (IPCIF) Financial Statements

144 Followers

IntelliPharmaCeutics International Financial Overview

IntelliPharmaCeutics International's market cap is currently ―. The company's EPS TTM is $-0.095; its P/E ratio is -1.56; IntelliPharmaCeutics International is scheduled to report earnings on April 21, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Aug 23May 23Feb 23Nov 22Aug 22
Income Statement-
Total Revenue$ 68.72K$ 480.20K$ 326.34K$ -36.75K$ 19.07K
Gross Profit$ -805.00K$ 480.20K$ 326.34K$ -36.75K$ 19.07K
EBIT$ -1.82M$ -2.23K$ -304.98K$ -804.83K$ -1.07M
EBITDA$ -1.78M$ 38.31K-$ -753.21K$ -1.02M
Net Income Common Stockholders$ -1.89M$ -54.12K$ -355.74K$ -874.73K$ -1.13M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 400.10K$ 159.27K$ 0.00$ 83.72K$ 79.65K
Total Assets$ 1.57M$ 1.74M$ 747.31K$ 1.16M$ 1.44M
Total Debt$ 2.22M$ 2.24M$ 0.00$ 2.33M$ 2.01M
Net Debt$ 1.82M$ 2.08M$ 0.00$ 2.24M$ 1.93M
Total Liabilities$ 14.44M$ 12.72M-$ 12.01M$ 11.59M
Stockholders Equity$ -12.88M$ -10.99M$ 0.00$ -10.58M$ -10.15M
Cash Flow-
Free Cash Flow$ 240.83K$ 89.73K-$ -195.93K$ -293.15K
Operating Cash Flow$ 240.83K$ 89.73K-$ -195.93K$ -293.15K
Investing Cash Flow-----
Financing Cash Flow---$ 200.00K-
Currency in USD

IntelliPharmaCeutics International Earnings and Revenue History

IntelliPharmaCeutics International Debt to Assets

IntelliPharmaCeutics International Cash Flow

IntelliPharmaCeutics International Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis